Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

The development of gastrointestinal stromal tumors (GISTs) is largely driven by mutations in the KIT and PDGFRα genes. Imatinib mesylate is an oral small molecular tyrosine kinase inhibitor that mainly targets abl, c-KIT, and PDGFRα. Imatinib achieves disease control in approximately 70%–85% of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Spitaleri, Gianluca, Biffi, Roberto, Barberis, Massimo, Fumagalli, Caterina, Toffalorio, Francesca, Catania, Chiara, Noberasco, Cristina, Lazzari, Chiara, de Marinis, Filippo, De Pas, Tommaso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548749/
https://www.ncbi.nlm.nih.gov/pubmed/26316776
http://dx.doi.org/10.2147/OTT.S81558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548749/
https://www.ncbi.nlm.nih.gov/pubmed/26316776
http://dx.doi.org/10.2147/OTT.S81558

Ejemplares similares